Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Certara, Inc.

CERTNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed May 13, 2026Accepted May 13, 2026, 4:48 PM EDTFiling CIK 1827090Accession 0001628991-26-000006
Share

Structured filing — 4

form4-05132026_080501.xml

Open full document ↗

Filing details

Report period
2026-05-11
Issuer
Certara, Inc.
Issuer CIK
0001827090
Trading symbol
CERT

Reporting owner 1

Name
Gallagher John E
Reporting owner CIK
0001628991
Relationship
Officer
Officer title
Chief Financial Officer
Address
C/O CERTARA, INC., 4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR, PA, 19087

Derivative transactions

Derivative transactions · 4 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Performance Stock Units[F1]2026-05-11D · Form 4102,522D0[F1][F1]Common Stock102,5220D
Performance Stock Units[F1]2026-05-11A · Form 4102,522A0[F1][F1]Common Stock102,522102,522D
Restricted Stock Units[F2]2026-05-11A · Form 4129,629A0[F2]2029-04-01Common Stock129,629129,629D
Performance Stock Units[F3]2026-05-11A · Form 4194,444A0[F3][F3]Common Stock194,444194,444D
Table key
D · Form 4
Disposition to the issuer under Rule 16b-3(e)
D
Direct
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired

Footnotes

F1
Each Certara, Inc. ("Company") performance stock unit ("PSU") was granted on May 20, 2025, pursuant to the terms of the 2025 Long-Term Incentive Plan for Company executives approved by the Compensation Committee of the Company's Board of Directors, under the Certara 2020 Incentive Plan (the "2020 Incentive Plan"). Each PSU represents a conditional right to receive one share of Company common stock. The reporting person will be entitled to receive a number of shares between 0% and 200% of the target amount reported based on the Company's performance against certain total shareholder return thresholds through the period ending on March 31, 2028.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6
F2
Each restricted stock unit ("RSU") was granted on May 11, 2026, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. The RSUs will vest and settle in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029.↩ 1↩ 2
F3
Each Company PSU was granted on May 11, 2026, pursuant to the terms of the 2026 Long-Term Incentive Plan for Company executives approved by the Compensation Committee of the Company's Board of Directors, under the 2020 Incentive Plan. Each PSU represents a conditional right to receive one share of Company common stock. The reporting person will be entitled to receive a number of shares between 0% and 200% of the target amount reported based on the Company's performance against certain total shareholder return thresholds through the period ending on March 31, 2029.↩ 1↩ 2↩ 3

Signature 1

Signed
/s/ Daniel D. Corcoran, as Attorney-in-Fact for John E. Gallagher
Date
2026-05-13

Company context

Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.

Current securities

Recent company filings

  1. Regulation FD DisclosureAug 7, 2026
  2. 10-Q filingAug 4, 2026
  3. Results of Operations and Financial ConditionAug 4, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 4, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJun 17, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.